Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
The effect of ACE inhibitor and angiotensin II receptor antagonist therapyon serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA
Autore:
Schmidt, A; Gruber, U; Bohmig, G; Koller, E; Mayer, G;
Indirizzi:
Univ Vienna, Dept Med 3, Div Nephrol & Dialysis, A-1090 Vienna, Austria Univ Vienna Vienna Austria A-1090 rol & Dialysis, A-1090 Vienna, Austria
Titolo Testata:
NEPHROLOGY DIALYSIS TRANSPLANTATION
fascicolo: 5, volume: 16, anno: 2001,
pagine: 1034 - 1037
SICI:
0931-0509(200105)16:5<1034:TEOAIA>2.0.ZU;2-Q
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONVERTING ENZYME-INHIBITION; HEALTHY-SUBJECTS; CYCLOSPORINE;
Keywords:
ACE inhibitors; angiotensin II receptor antagonists; CsA; renal transplantation; serum potassium; serum uric acid;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Schmidt, A Univ Vienna, Dept Med 3, Div Nephrol & Dialysis, Wahringer Gurtel 18-20, A-1090 Vienna, Austria Univ Vienna Wahringer Gurtel 18-20 ViennaAustria A-1090 stria
Citazione:
A. Schmidt et al., "The effect of ACE inhibitor and angiotensin II receptor antagonist therapyon serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CsA", NEPH DIAL T, 16(5), 2001, pp. 1034-1037

Abstract

Background. The angiotensin II (AT II) type I receptor antagonist losartanhas been reported to increase urinary uric acid and potassium excretion. These effects might be beneficial in cyclosporin (CsA)-treated renal transplant recipients, who frequently suffer from hyperuricaemia and hyperkalaemia. Methods. In this prospective, open, randomized, two-way cross-over study we included 13 hypertensive CsA-treated patients after renal transplantationand administered either the angiotensin-converting enzyme (ACE) inhibitorsenalapril or losartan. Laboratory parameters, 24-h urinary protein excretion, and mean 24-h arterial blood pressure (MAP) were checked after 3 weeks treatment with enalapril, after a wash-out period of 2 weeks. and before and after a 3-week treatment course with losartan. Results, Both drugs slightly reduced MAP (losartan from 97 +/- 6 to 94 +/-9 and enalapril to 93 +/- 8 mmHg). Serum potassium levels significantly increased during enalapril therapy (from 4.3 +/- 0.5 to 4.8 +/- 0.4 mmol/l. P<0.05), as did. although not significantly, uric acid concentrations (from 7.8 +/- 1.9 to 8.2 +/- 1.8 mg/dl P=0.5). Losartan, on the contrary, only mildly affected serum potassium (4.3 +/- 0.5 vs 4.5 +/- 0.5 mmol/l, P=0.25) and serum uric acid decreased (from 7.8 +/- 2.4 to 7.3 +/- 1.8 mg/dl, P=0.6). Serum aldosterone and urinary aldosterone excretion were significantly reduced only during ACE inhibitor treatment, which might explain the variableeffects on potassium homeostasis. Conclusion. Losartan may be a useful agent to reduce blood pressure and serum uric acid levels in renal transplant recipients treated with CsA. Furthermore, in this high-risk population, the effects on serum potassium levelsare less mal ked with losartan than with enalapril.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 20/01/20 alle ore 04:46:54